These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24284914)

  • 21. Antibodies to watch in 2024.
    Crescioli S; Kaplon H; Chenoweth A; Wang L; Visweswaraiah J; Reichert JM
    MAbs; 2024; 16(1):2297450. PubMed ID: 38178784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.
    Udata C; Garzone PD; Gumbiner B; Joh T; Liang H; Liao KH; Williams JH; Meng X
    J Clin Pharmacol; 2017 Jul; 57(7):855-864. PubMed ID: 28181260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.
    Chackerian B; Remaley A
    Curr Opin Lipidol; 2016 Aug; 27(4):345-50. PubMed ID: 27389630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
    Ballantyne CM; Neutel J; Cropp A; Duggan W; Wang EQ; Plowchalk D; Sweeney K; Kaila N; Vincent J; Bays H
    Am J Cardiol; 2015 May; 115(9):1212-21. PubMed ID: 25784512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Chen Q; Wu G; Li C; Qin X; Liu R; Zhang M
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):343-353. PubMed ID: 31823301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PCSK9 Monoclonal Antibodies: An Overview.
    Kaddoura R; Orabi B; Salam AM
    Heart Views; 2020; 21(2):97-103. PubMed ID: 33014302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.
    Zhang J; Tecson KM; Rocha NA; McCullough PA
    Proc (Bayl Univ Med Cent); 2018 Apr; 31(2):180-184. PubMed ID: 29706812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
    Kakkar AK; Balakrishnan S
    J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bococizumab for the treatment of hypercholesterolaemia.
    Ferri N; Corsini A; Sirtori CR; Ruscica M
    Expert Opin Biol Ther; 2017 Feb; 17(2):237-243. PubMed ID: 28060539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
    Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
    J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach.
    Scherer N; Dings C; Böhm M; Laufs U; Lehr T
    J Clin Pharmacol; 2017 Jul; 57(7):846-854. PubMed ID: 28263403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY.
    Strat AL; Ghiciuc CM; Lupuşoru CE; Mitu F
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):228-32. PubMed ID: 27483697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
    Koren MJ; Roth EM; McKenney JM; Gipe D; Hanotin C; Ferrand AC; Wu R; Dufour R
    Postgrad Med; 2015 Mar; 127(2):125-32. PubMed ID: 25609019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience.
    Farnier M
    Curr Opin Lipidol; 2016 Dec; 27(6):597-604. PubMed ID: 27755114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alirocumab: targeting PCSK9 to treat hypercholesterolemia.
    Pećin I; Reiner Ž
    Drugs Today (Barc); 2015 Dec; 51(12):681-7. PubMed ID: 26798848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.